Recent progress in tumour vaccine development

I. Caroline Le Poole*, Hemamalini Bommiasamy, W. Martin Kast

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity, several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.

Original languageEnglish (US)
Pages (from-to)971-981
Number of pages11
JournalExpert Opinion on Investigational Drugs
Issue number6
StatePublished - Jun 1 2003


  • Adjuvants
  • Antibodies
  • Antigens
  • Dendritic cells
  • Immune monitoring
  • Immunotherapy
  • T cells
  • Tumour vaccine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Recent progress in tumour vaccine development'. Together they form a unique fingerprint.

Cite this